Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again
Epratuzumab (anti-CD22) is a humanized monoclonal antibody that recognizes a pan-B-cell marker. It potentially downregulates B cell activity through negative signaling, as well as depleting B cells moderately. The uncontrolled series discussed by Dörner and colleagues in this issue of Arthritis Rese...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2006
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526641/ |